{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:22:26Z","timestamp":1793830946962,"version":"4.6.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","award":["NCC2110790"],"award-info":[{"award-number":["NCC2110790"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","award":["NCC23105603"],"award-info":[{"award-number":["NCC23105603"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","award":["NCC24H12701"],"award-info":[{"award-number":["NCC24H12701"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ijgc.2025.101630","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T11:56:40Z","timestamp":1736423800000},"page":"101630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A randomized, multicenter, open-label phase III trial of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in platinum-resistant recurrent ovarian cancer: a rationale and study design of the KOV-HIPEC-02 trial"],"prefix":"10.1016","volume":"35","author":[{"given":"Ji Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunyoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Yoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myong Cheol","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijgc.2025.101630_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN\u00a0estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101630_bib2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ygyno.2014.11.072","article-title":"A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer","volume":"136","author":"Chiva","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101630_bib3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/onc.2015.82","article-title":"Hyperthermic intraperitoneal chemotherapy\u00a0leads to an anticancer immune response via exposure of cell surface heat shock protein 90","volume":"35","author":"Zunino","year":"2016","journal-title":"Oncogene"},{"issue":"14","key":"10.1016\/j.ijgc.2025.101630_bib4","first-page":"1363","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.ijgc.2025.101630_bib5","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","article-title":"Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial","volume":"157","author":"Lim","year":"2022","journal-title":"JAMA Surg"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101630_bib6","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejso.2011.03.134","article-title":"Perioperative fast track program in intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery in advanced ovarian cancer","volume":"37","author":"Cascales","year":"2011","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2025.101630_bib7","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.ejso.2013.09.030","article-title":"Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients","volume":"39","author":"Bakrin","year":"2013","journal-title":"Eur J Surg Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2025.101630_bib8","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.21.00605","article-title":"Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK team ovary phase II study","volume":"39","author":"Zivanovic","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101630_bib9","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ygyno.2022.10.010","article-title":"Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: a meta-analysis","volume":"167","author":"Kim","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2025.101630_bib10","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijgc.2025.101630_bib11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fphar.2020.00343","article-title":"The drug-resistance mechanisms of five platinum-based antitumor agents","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Pharmacol"},{"issue":"13","key":"10.1016\/j.ijgc.2025.101630_bib12","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the Aurelia open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2025.101630_bib13","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FRalpha-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.ijgc.2025.101630_bib14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/10717544.2020.1862364","article-title":"Simulating drug penetration during hyperthermic intraperitoneal chemotherapy","volume":"28","author":"L\u00f6ke","year":"2021","journal-title":"Drug Deliv"},{"issue":"34","key":"10.1016\/j.ijgc.2025.101630_bib15","doi-asserted-by":"crossref","first-page":"13650","DOI":"10.1073\/pnas.1203326109","article-title":"BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2\/M checkpoint activation","volume":"109","author":"Stecklein","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101630_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1515\/pp-2017-0003","article-title":"Overview of the optimal perioperative intraperitoneal chemotherapy regimens used in current clinical practice","volume":"2","author":"Van der Speeten","year":"2017","journal-title":"Pleura Peritoneum"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25001434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25001434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:42:51Z","timestamp":1775022171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25001434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1048891X25001434"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101630","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized, multicenter, open-label phase III trial of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in platinum-resistant recurrent ovarian cancer: a rationale and study design of the KOV-HIPEC-02 trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101630","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"101630"}}